Impact of Nasopharyngeal FilmArray Respiratory Panel Results on Antimicrobial Decisions in Hospitalized Patients

Table 2

Common antimicrobial regimens utilized to initiate (groups B and C), discontinue (group B), or escalate (group C) therapy in patients with positive (+) or negative (−) NP-FARP.

Group (+) B
Antibiotics started	59
Anti-MRSA + β-lactam + atypical pathogen coverage	19
Atypical respiratory pathogen	14
β-lactam + atypical pathogen coverage	10
Antibiotics discontinued	59
Atypical respiratory pathogen	16
Anti-MRSA + β-lactam	14
β-lactam	9
Anti-MRSA	6
Group (−) B
Antibiotics started	147
Anti-MRSA + β-lactam + atypical pathogen coverage	54
β-lactam + atypical pathogen coverage	29
β-lactam	27
Antibiotics discontinued	147
β-lactam	43
Anti-MRSA + β-lactam	43
Anti-MRSA	20
Group (+) C
Antibiotics started	56
Atypical pathogen coverage	18
β-lactam	11
Anti-MRSA + β-lactam + atypical pathogen coverage	8
Antibiotics escalated	11
Anti-MRSA + β-lactam	2
β-lactam	2
Atypical pathogen coverage	2
Group (−) C
Antibiotics started	171
Atypical pathogen coverage	49
β-lactam	27
β-lactam + atypical pathogen coverage	23
Anti-MRSA + β-lactam + atypical pathogen coverage	20
Anti-MRSA + β-lactam	18
Antibiotics escalated	42
Atypical pathogen coverage	12
β-lactam	11
Anti-MRSA	5

MRSA, methicillin-resistant Staphylococcus aureus.